Embody Post-Market Clinical Follow-Up Study
Launched by ZIMMER BIOMET · Feb 16, 2023
Trial Information
Current as of May 07, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The proposed investigation is a multi-center, prospective patient registry: subscapularis repair augmented with TAPESTRY® Biointegrative Implant after shoulder arthroplasty. The primary objective of this study is to evaluate the long-term integrity of the subscapularis tendon repair after shoulder arthroplasty augmented with TAPESTRY Biointegrative Implant, assessed by ultrasound 6 months postoperatively. Secondary objectives are to assess shoulder function (internal rotation strength), safety, and patient reported outcomes. Patients will be evaluated preoperatively, at the time of surgery,...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult, 21 years and older.
- • 2. Patient requires shoulder arthroplasty (anatomic or reverse) with subscapularis repair due to osteoarthritis, rotator cuff injury, rheumatoid arthritis and/or other inflammatory disorder, osteonecrosis, and/or post-traumatic injury (e.g., humerus fractures).
- • 3. Patients healthy enough to undergo primary anatomic or reverse shoulder arthroplasty, in the opinion of the investigator;
- • 4. Patients receiving shoulder arthroplasty with anticipated subscapularis tenotomy (ST) or subscapularis peel (SP).
- • 5. Intact rotator cuff including subscapularis tendon for anatomic shoulder arthroplasty or a repairable subscapularis tendon for reverse shoulder arthroplasty, as determined by preoperative examination or imaging, if indicated or available preoperatively. Imaging is not required for this assessment.
- • 6. Ability and willingness to comply with prescribed post-operative rehabilitation program.
- • 7. Ability and willingness to comply with follow-up visit schedule.
- • 8. Able to understand the informed consent process, including regulatory requirements such as HIPAA authorization, and document informed consent prior to completion of any study-related procedures.
- • 9. Ability to read, understand, and complete subject-reported outcomes in English.
- Exclusion Criteria:
- • 1. Shoulder arthroplasty requiring a lesser tuberosity osteotomy or revision arthroplasty.
- • 2. Prior index shoulder surgery requiring treatment to the subscapularis.
- • 3. Intraoperative identification of irreparable subscapularis tear (rTSA)
- • 4. Diabetic patients with hemoglobin A1c (HbA1c) level \>8% prior to surgery.
- • 5. Patients with inflammatory arthritis or patients that are immunocompromised, or patients that have a glenoid deficiency.
- • 6. Patients with a known history of hypersensitivity to bovine-derived materials.
- • 7. Hypersensitivity to poly(D,L-lactide) materials.
- • 8. Females of child-bearing potential who are pregnant or plan to become pregnant during the course of the study.
- • 9. Currently involved in any injury litigation or worker's compensation claims relating to the index shoulder.
- • 10. Enrolled, or plans to enroll, in another clinical trial during this study that would affect the outcomes of this study.
- • 11. History of non-compliance with medical treatment, physical therapy/rehabilitation, or clinical study participation.
About Zimmer Biomet
Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santa Barbara, California, United States
New Windsor, New York, United States
Carmel, Indiana, United States
Louisville, Kentucky, United States
Atlantis, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials